From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2024-04 · 16 (2)
DOI: 10.1002/dad2.12580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 14.04.2024. Verfasst von Sonal Sukreet und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences University of California-San Diego La Jolla California USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, National Institutes of Health.
Themen: Demenz
Abstract (Originalsprache)
Down syndrome (DS) is caused by a third copy of chromosome 21. Alzheimer's disease (AD) is a neurodegenerative condition characterized by the deposition of amyloid‐beta (Aβ) plaques and neurofibrillary tangles in the brain. Both disorders have elevated Aβ, tau, dysregulated immune response, and inflammation. In people with DS, Hsa21 genes like APP and DYRK1A are overexpressed, causing an accumulation of amyloid and neurofibrillary tangles, and potentially contributing to an increased risk of AD. As a result, people with DS are a key demographic for research into AD therapeutics and prevention. The molecular links between DS and AD shed insights into the underlying causes of both diseases and highlight potential therapeutic targets. Also, using biomarkers for early diagnosis and treatment monitoring is an active area of research, and genetic screening for high‐risk individuals may enable earlier intervention. Finally, the fundamental mechanistic parallels between DS and AD emphasize the necessity for continued research into effective treatments and prevention measures for DS patients at risk for AD. Genetic screening with customized therapy approaches may help the DS population in current clinical studies and future biomarkers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosciences University of California-San Diego La Jolla California USA.
- Department of Neurology, Alzheimer's Therapeutic Research Institute Keck School of Medicine of the University of Southern California San Diego California USA.
- Department Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute Keck School of Medicine of the University of Southern California San Diego California USA.
ORCID-Profile: Sonal Sukreet, Michael S Rafii, Robert A Rissman
Förderung
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Sukreet, S., Rafii, M. S., & Rissman, R. A. (2024). From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 16(2). https://doi.org/10.1002/dad2.12580
Vancouver
Sukreet S, Rafii MS, Rissman RA. From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2024;16(2). doi:10.1002/dad2.12580
BibTeX
@article{Sukreet2024,
author = {Sukreet, Sonal and Rafii, Michael S and Rissman, Robert A},
title = {From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2024},
volume = {16},
number = {2},
doi = {10.1002/dad2.12580}
}
EUVIMED